MediPharm Labs Statistics
Total Valuation
MediPharm Labs has a market cap or net worth of 21.05 million. The enterprise value is 14.90 million.
| Market Cap | 21.05M |
| Enterprise Value | 14.90M |
Important Dates
The last earnings date was Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 415.14M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.01% |
| Shares Change (QoQ) | +0.80% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 383.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.70 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.87 |
| EV / Sales | 0.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.28 |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.00.
| Current Ratio | 3.61 |
| Quick Ratio | 1.86 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -10.11 |
Financial Efficiency
Return on equity (ROE) is -16.05% and return on invested capital (ROIC) is -7.64%.
| Return on Equity (ROE) | -16.05% |
| Return on Assets (ROA) | -6.42% |
| Return on Invested Capital (ROIC) | -7.64% |
| Return on Capital Employed (ROCE) | -13.46% |
| Revenue Per Employee | 185,797 |
| Profits Per Employee | -32,280 |
| Employee Count | 161 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 2.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.28% in the last 52 weeks. The beta is 0.32, so MediPharm Labs's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -5.28% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 41.83 |
| Average Volume (20 Days) | 117,542 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MediPharm Labs had revenue of 29.91 million and -5.20 million in losses. Loss per share was -0.01.
| Revenue | 29.91M |
| Gross Profit | 10.30M |
| Operating Income | -4.05M |
| Pretax Income | -5.20M |
| Net Income | -5.20M |
| EBITDA | -2.55M |
| EBIT | -4.05M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 6.00 million in cash and 86,966 in debt, giving a net cash position of 5.91 million.
| Cash & Cash Equivalents | 6.00M |
| Total Debt | 86,966 |
| Net Cash | 5.91M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 30.08M |
| Book Value Per Share | 0.07 |
| Working Capital | 16.00M |
Cash Flow
In the last 12 months, operating cash flow was -4.42 million and capital expenditures -121,752, giving a free cash flow of -4.54 million.
| Operating Cash Flow | -4.42M |
| Capital Expenditures | -121,752 |
| Free Cash Flow | -4.54M |
| FCF Per Share | n/a |
Margins
Gross margin is 34.42%, with operating and profit margins of -13.54% and -17.37%.
| Gross Margin | 34.42% |
| Operating Margin | -13.54% |
| Pretax Margin | -17.37% |
| Profit Margin | -17.37% |
| EBITDA Margin | -8.52% |
| EBIT Margin | -13.54% |
| FCF Margin | n/a |
Dividends & Yields
MediPharm Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.01% |
| Shareholder Yield | n/a |
| Earnings Yield | -24.69% |
| FCF Yield | -21.55% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediPharm Labs has an Altman Z-Score of -2.03. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.03 |
| Piotroski F-Score | n/a |